万古霉素联合哌拉西林-他唑巴坦与危重症成人肌酐和胱抑素C早期变化的前瞻性队列研究
该前瞻性队列研究纳入MESSI队列中接受万古霉素联合哌拉西林-他唑巴坦或万古霉素联合头孢吡肟治疗≥48小时的739例患者,比较抗生素启动前与第2天肌酐、胱抑素C和BUN的变化。万古霉素联合哌拉西林-他唑巴坦与第2天肌酐升高8.04%(95%CI 1.21,15.34)及肌酐定义AKI发生率升高相关(RR 1.34,95%CI 1.01,1.78),但与胱抑素C变化(-5.63%,95%CI -18.19,8.86)、BUN变化(-4.51%,95%CI -12.83,4.59)、透析(RR 0.63,95%CI 0.31,1.29)或死亡(RR 1.05,95%CI 0.79,1.41)无关。作者认为这些结果支持万古霉素联合哌拉西林-他唑巴坦对肌酐的影响代表假性毒性。
要点
- 万古霉素联合哌拉西林-他唑巴坦与第2天肌酐百分比升高8.04%(95%CI 1.21,15.34)相关。
- 万古霉素联合哌拉西林-他唑巴坦与肌酐定义AKI发生率升高相关:RR 1.34(95%CI 1.01,1.78)。
- 万古霉素联合哌拉西林-他唑巴坦与胱抑素C变化-5.63%(95%CI -18.19,8.86)和BUN变化-4.51%(95%CI -12.83,4.59)无关。
- 万古霉素联合哌拉西林-他唑巴坦与透析(RR 0.63,95%CI 0.31,1.29)和死亡(RR 1.05,95%CI 0.79,1.41)无关。
- 作者认为万古霉素联合哌拉西林-他唑巴坦对肌酐的影响代表假性毒性,而非真实肾损伤。
适用人群与场景
- 纳入MESSI前瞻性队列中接受万古霉素联合哌拉西林-他唑巴坦或万古霉素联合头孢吡肟治疗≥48小时的ICU患者。
- 共739例患者,其中万古霉素联合哌拉西林-他唑巴坦组297例,万古霉素联合头孢吡肟组442例;192例有胱抑素C测量。
研究设计与关键结果
- 研究类型为前瞻性队列研究(MESSI队列),纳入739例ICU患者,万古霉素联合哌拉西林-他唑巴坦组297例,万古霉素联合头孢吡肟组442例;192例有胱抑素C测量。
- 主要终点:万古霉素联合哌拉西林-他唑巴坦与第2天肌酐百分比升高8.04%(95%CI 1.21,15.34)相关,肌酐定义AKI发生率升高(RR 1.34,95%CI 1.01,1.78)。
- 关键次要终点:胱抑素C变化-5.63%(95%CI -18.19,8.86),BUN变化-4.51%(95%CI -12.83,4.59),透析RR 0.63(95%CI 0.31,1.29),死亡RR 1.05(95%CI 0.79,1.41),均无统计学显著关联。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为万古霉素联合哌拉西林-他唑巴坦对肌酐的影响代表假性毒性,而非真实肾损伤。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Although dozens of studies have associated vancomycin + piperacillin-tazobactam with increased acute kidney injury (AKI) risk, it is unclear whether the association represents true injury or a pseudotoxicity characterized by isolated effects on creatinine secretion. We tested this hypothesis by contrasting changes in creatinine concentration after antibiotic initiation with changes in cystatin C concentration, a kidney biomarker unaffected by tubular secretion.
METHODS: We included patients enrolled in the Molecular Epidemiology of SepsiS in the ICU (MESSI) prospective cohort who were treated for ≥ 48 h with vancomycin + piperacillin-tazobactam or vancomycin + cefepime. Kidney function biomarkers [creatinine, cystatin C, and blood urea nitrogen (BUN)] were measured before antibiotic treatment and at day two after initiation. Creatinine-defined AKI and dialysis were examined through day-14, and mortality through day-30. Inverse probability of treatment weighting was used to adjust for confounding. Multiple imputation was used to impute missing baseline covariates.
RESULTS: The study included 739 patients (vancomycin + piperacillin-tazobactam n = 297, vancomycin + cefepime n = 442), of whom 192 had cystatin C measurements. Vancomycin + piperacillin-tazobactam was associated with a higher percentage increase of creatinine at day-two 8.04% (95% CI 1.21, 15.34) and higher incidence of creatinine-defined AKI: rate ratio (RR) 1.34 (95% CI 1.01, 1.78). In contrast, vancomycin + piperacillin-tazobactam was not associated with change in alternative biomarkers: cystatin C: - 5.63% (95% CI - 18.19, 8.86); BUN: - 4.51% (95% CI - 12.83, 4.59); or clinical outcomes: dialysis: RR 0.63 (95% CI 0.31, 1.29); mortality: RR 1.05 (95%CI 0.79, 1.41).
CONCLUSIONS: Vancomycin + piperacillin-tazobactam was associated with creatinine-defined AKI, but not changes in alternative kidney biomarkers, dialysis, or mortality, supporting the hypothesis that vancomycin + piperacillin-tazobactam effects on creatinine represent pseudotoxicity.
参考来源
- Miano TA, Hennessy S, Yang W, et al. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study. Intensive Care Med. 2022. PMID: 35833959. doi:10.1007/s00134-022-06811-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。